UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2003
PROTEIN DESIGN LABS, INC.
(Exact name of registrant as specified in its charter)
|
Delaware |
000-19756 |
94-3023969 |
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
||
|
|
||
|
34801 Campus Drive |
||
|
Fremont, California 94555 |
||
|
(Address of principal executive offices) (Zip Code) |
||
|
|
||
|
|
||
|
Registrant’s telephone number, including area code: (510) 574-1400 |
||
Not Applicable
(Former name or former address, if changed since last report)
Item 5. Other Events
On August 15, 2003, Protein Design Labs, Inc. (“PDL”) issued a press release regarding the status of its Genentech humanization patent license arrangement. A copy of PDL’s press release is attached hereto as Exhibit 99.1.
Item 7. Financial Statements and Exhibits
(c) Exhibits
99.1 Press Release dated August 15, 2003.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
PROTEIN DESIGN LABS, INC. |
||
|
|
|
|
|
|
|
|
|
|
|
Date: August 15, 2003 |
By: |
/s/ Glen Sato |
|
|
|
|
Glen Sato |
|
|
|
|
Senior Vice President and Chief Financial |
|
|
|
|
Officer |
|
3
EXHIBIT INDEX
|
Exhibit No. |
Description |
|
|
|
|
99.1 |
Press Release dated August 15, 2003. |
4